AAM
ARCT icon

Advisors Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Advisors Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,330
Closed -$37K – 1465
2022
Q2 		$37K Sell
2,330
-3,233
-58% -$63.4K ﹤0.01% 1407
2022
Q1 		$150K Sell
5,563
-5,306
-49% -$135K ﹤0.01% 1292
2021
Q4 		$402K Sell
10,869
-453
-4% -$18.5K 0.01% 1063
2021
Q3 		$541K Buy
11,322
+10
+0.1% +$448 0.01% 978
2021
Q2 		$383K Buy
11,312
+4,836
+75% +$164K 0.01% 1078
2021
Q1 		$267K Buy
6,476
+4,058
+168% +$242K ﹤0.01% 1155
2020
Q4 		$105K Buy
+2,418
New +$164K ﹤0.01% 1352

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Advisors Asset Management's ARCT Position: Q3 2022 in Review

Advisors Asset Management sold out of Arcturus Therapeutics (ARCT) in Q3 2022, closing a stake of 2,330 shares — an estimated $37K sold.

Advisors Asset Management first reported a position in ARCT in Q4 2020 and held it in 7 quarters. The position peaked at $541K in Q3 2021. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

  • Advisors Asset Management reported no remaining Arcturus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Advisors Asset Management sold 2,330 Arcturus Therapeutics shares in Q3 2022, an estimated $37K.
  • Advisors Asset Management first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 7 quarters.
  • Advisors Asset Management's Arcturus Therapeutics position peaked at $541K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on Advisors Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.